AUROPHARMA Intraday Analysis...

AUROPHARMA Share Price

Open 1187.00 Change Price %
High 1189.15 1 Day -1.25 -0.11
Low 1165.00 1 Week 24.50 2.12
Close 1179.85 1 Month 90.35 8.29
Volume 680189 1 Year 753.85 176.96
52 Week High 1192.00
52 Week Low 408.10
AUROPHARMA Important Levels
Resistance 2 1202.24
Resistance 1 1193.01
Pivot 1178.00
Support 1 1166.69
Support 2 1157.46
AUROPHARMA CURRENT MONTH FUTURE
Close 1179.80
Contracts Traded 6598
Open Intrest 5599250
Change In O.I -494250
Lot Size 250
AUROPHARMA CURRENT MONTH OPTION
Most Active Call 1200
Most Active put 1140
Highest O.I Buildup Call 1200
Highest O.I Buildup Put 1000
Expiry Date 29-Jan-2015
AUROPHARMA ALL MONTHS OPTIONS
For All AUROPHARMA Options Click Here
NSE INDIA Most Active Stocks
NIFTY 8835.60 0.85%
SUZLON 14.85 -7.19%
UNITECH 16.95 1.19%
CNXIT 11885.15 0.29%
JPASSOCIAT 26.60 3.50%
GMRINFRA 16.80 -0.88%
DISHTV 79.40 6.65%
SBIN 327.45 0.86%
KPIT 219.00 3.20%
ADANIPOWER 50.85 7.62%
More..
NSE INDIA Top Gainers Stocks
JIKIND 1.20 20.00%
SPARC 334.75 19.79%
KARURKCP 60.00 19.28%
RTNINFRA 2.75 17.02%
IPRINGLTD 137.00 16.50%
WALCHANNAG 242.40 15.93%
VISUINTL 0.80 14.29%
COMPUAGE 162.00 11.76%
SATHAISPAT 43.60 10.52%
ELECTHERM 24.20 10.00%
More..
NSE INDIA Top Losers Stocks
TATACOFFEE 102.30 -89.82%
ANTGRAPHIC 0.15 -25.00%
VKSPL 0.20 -20.00%
ATNINTER 0.25 -16.67%
REISIXTEN 0.35 -12.50%
ZUARI 252.45 -12.25%
LCCINFOTEC 0.40 -11.11%
HCL-INSYS 44.30 -10.69%
ZENITHBIR 0.90 -10.00%
KANDAGIRI 70.20 -10.00%
More..

Aurobindo Pharma Limited (NSE: AUROPHARMA)

AUROPHARMA Technical Analysis 5
As on 23rd Jan 2015 AUROPHARMA Share Price closed @ 1179.85 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 795.84 & Strong Buy for SHORT-TERM with Stoploss of 1118.89 we also expect STOCK to react on Following IMPORTANT LEVELS.
AUROPHARMA Target for January
1st Target up-side 1223.88
2nd Target up-side 1285.69
3rd Target up-side 1347.5
1st Target down-side 1047.52
2nd Target down-side 985.71
3rd Target down-side 923.9
AUROPHARMA Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 68.32 Sideways
MFI (14) MFI is 54.52 Sideways
CCI (20) CCI is -13.16 Sideways
WILLIAM %R (14) William %R is -42.53 Sideways
ADX (14) ADX is Above 20 & +DI is Above -DI Up Trend
PSAR Stoploss For Long Buy 658.30
10 Day Avg Volume Traded 16.95 % More then 10 Day Average Volume
AUROPHARMA Other Details
Segment EQ
Market Capital 25150871552.00
Sector Pharmaceuticals
Industry
Offical website
AUROPHARMA Address
AUROPHARMA
N/A
AUROPHARMA Latest News
Aurobindo Pharma tanks 5% despite strong fourth quarter nos   Moneycontrol.com   - 02nd Jun 14
TABLE-India's Aurobindo Pharma Jan-March net profit rises   Reuters   - 31st May 14
Aurobindo Pharma Q4 net spurts to Rs 501 cr   Hindu Business Line   - 30th May 14
Morgan Stanley sells Aurobindo Pharma shares worth Rs 116cr   Moneycontrol.com   - 30th May 14
Buy Aurobindo Pharma Ltd with a target of Rs 670: Mitesh Thacker   Economic Times   - 28th May 14
Reddy Becomes Billionaire as India's Aurobindo Shares Triple   Bloomberg   - 27th May 14
Aurobindo Pharma to announce FY14 results on May 30, 2014   Equity Bulls   - 27th May 14
Aurobindo Pharma rallies nearly 3%, hits fresh 52-week high on MSCI inclusion   Economic Times   - 15th May 14
Aurobindo Pharma hits new high   Business Standard   - 13th May 14
Aurobindo Pharma Limited   Moneycontrol.com   - 12th May 14
Interactive Technical Analysis Chart Aurobindo Pharma Limited ( AUROPHARMA NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Aurobindo Pharma Limited
AUROPHARMA Business Profile
Aurobindo Pharm is in the Pharmaceuticals sector. Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others. Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. Aurobindo Pharma is among the largest filers of DMFs and ANDAs from India. The current market capitalisation stands at Rs 8,284.96 crore.The company has reported a consolidated sales of Rs 1913.86 crore and a Net Profit of Rs 233.86 crore for the quarter ended Sep 2013. The company management includes K Ragunathan - Non Executive Chairman, K Nithyananda Reddy - Vice Chairman & Whole Time Dir, N Govindarajan - Managing Director, M Sivakumaran - Whole Time Director, M Madan Mohan Reddy - Whole Time Director, P V Ramprasad Reddy - Non Executive Director, P Sarath Chandra Reddy - Non Executive Director, M Sitarama Murthy - Non Executive Director, D Rajagopala Reddy - Non Executive Director, C Channa Reddy - Non Executive Director. It is listed on the BSE with a BSE Code of 524804 and the NSE with an NSE Code of AUROPHARMA. Its Registered office is at Plot No. 2, Maitrivihar,,Ameerpet Hyderabad,Andhra Pradesh - 500038.